BOLD vs. ZNTL, CVAC, ETNB, CNTA, PRTC, COGT, EOLS, PLRX, PRAX, and NRIX
Should you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Zentalis Pharmaceuticals (ZNTL), CureVac (CVAC), 89bio (ETNB), Centessa Pharmaceuticals (CNTA), PureTech Health (PRTC), Cogent Biosciences (COGT), Evolus (EOLS), Pliant Therapeutics (PLRX), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.
Audentes Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals' return on equity of 0.00% beat Audentes Therapeutics' return on equity.
Zentalis Pharmaceuticals presently has a consensus price target of $31.67, suggesting a potential upside of 165.44%. Audentes Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 169.01%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Audentes Therapeutics is more favorable than Zentalis Pharmaceuticals.
In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Audentes Therapeutics. MarketBeat recorded 8 mentions for Zentalis Pharmaceuticals and 2 mentions for Audentes Therapeutics. Audentes Therapeutics' average media sentiment score of 0.49 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Audentes Therapeutics received 418 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 69.22% of users gave Audentes Therapeutics an outperform vote while only 65.00% of users gave Zentalis Pharmaceuticals an outperform vote.
Summary
Audentes Therapeutics beats Zentalis Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Get Audentes Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Audentes Therapeutics Competitors List
Related Companies and Tools
